With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10581-12-1,Tetramethylammonium acetate,as a common compound, the synthetic route is as follows.
To a solution of compound 3 (20g, 42.8mmol, 1.0eq) in Toluene (200mL) was added tetra methyl ammonium acetate (14.3g, 54.8mmol, 1.28eq) at rt. The mixture was heated to reflux for 16h. TLC analysis indicated formation of a polar spot. Then the reaction mass was extracted with EtOAc (2 X 200m L) and washed with water (2 X 100ml_) and brine (2 X 100ml_). The organic layer was dried under reduced pressure. The residue (40 g) was taken up with 80ml_ of 2-prpoanol. The mixture was stirred at 0C for 30 mins and the resulting Crystalline product was collected under dried under vaccum to give compound 4 (12 g, 68%) as a pale yellow color Solid. LCMS: 79.34% with m/z 356.24 (M+H):
10581-12-1, As the paragraph descriping shows that 10581-12-1 is playing an increasingly important role.
Reference£º
Patent; ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR); AL-AWAR, Rima; ISAAC, Methvin; CHAU, Anh My; MAMAI, Ahmed; WATSON, Iain; PODA, Gennady; SUBRAMANIAN, Pandiaraju; WILSON, Brian; UEHLING, David; PRAKESCH, Michael; JOSEPH, Babu; MORIN, Justin-Alexander; (441 pag.)WO2019/153080; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI